Payment for drug therapy in children with acute lymphoblastic leukemia within compulsory health insurance: current practice and possible ways of improvement

М. В. Сура(Russian Medical Academy of Continuous Professional Education), Галина Новичкова(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Д. С. Блинов(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), T Boyarskaya(Center for Assessment), A. A. Makhrova(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Alexander Karachunsky(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology)
Medical Technologies Assessment and Choice
September 8, 2023
10.17116/medtech20234503147
Cited by 0

Related Papers

HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome
|Journal of Allergy and Clinical Immunology|2020|29
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
|Cells|2019|19
Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
|International Journal of Molecular Sciences|2022|16
Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice
|Journal of Advanced Pharmaceutical Technology amp Research|2018|14
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
|Life|2020|13